Boehringer

Boehringer Ingelheim Faces Legal Heat as Zantac’s Toxic Risks Come to Light

by

Chicago, Illinois — A colorectal cancer patient claimed in an Illinois courtroom that Boehringer Ingelheim failed to address knowledge of serious safety concerns regarding the active ingredient in its over-the-counter drug Zantac. The patient asserted that the company took insufficient actions despite years of warnings that the compound could degrade into a harmful substance. During the trial, the plaintiff recounted their experience with Zantac, alleging that the pharmaceutical company merely altered the color of its tablets rather than addressing the underlying issues. The patient’s testimony raises questions about Boehringer Ingelheim’s commitment to consumer safety and … Read more

Federal Judge Hints at Protection for Government in Drug Pricing Battle with Boehringer Ingelheim

by

In a recent judicial hearing, a judge from the Second Circuit hinted that the federal government might be protected against lawsuits challenging its push for reduced medication prices for Medicare and Medicaid beneficiaries. During the proceedings, the focus was on a case involving Boehringer Ingelheim, a prominent pharmaceutical company, which has raised concerns about the mandates affecting their pricing structures. The debate centers on whether federal mandates for lowering drug prices for government-supported health programs stand on solid legal ground or if they infringe upon the rights of pharmaceutical companies. The judge’s commentary suggested a … Read more